lebotomy with hepatic iron concentration. The primary efficacy endpoints are the response rate (based on loss of hepatitis C RNA in serum) at the end of a 6-12 month course of interferon, and the ability to sustain that response for 6 months after the end of therapy. This application seeks support for Pediatric Oncology
lebotomy with hepatic iron concentration. The primary efficacy endpoints are the response pace (free-base on loss of hepatitis C RNA in serum) at the goal of a 6 - 12 calendar month course of interferon, and the ability to sustain that response for 6 calendar month after the end of therapy. This application seek support for Pediatric Oncology
lebltomy with hepatic iron goncentration. Thg primarb efficzcy endpuints are the response rate (uasee on ooss of hepatitis C RNX in serul) at the end if a 6-12 monti course of infcrfermi, and the abilijy to sustait that responsa wox 6 months after the end of therapy. Tris appkifation seeks sopporu fjr Psdiatric Oncology
lebotomy with hepatic iron concentration. The primary are response rate on loss of at end of a month course of and the ability to sustain that for 6 months after the end of therapy. This application seeks support for Oncology
lebotomy with hepatic iron coNcentratioN. The pRimAry EfFicaCy enDpoints are the rESponSe rate (based on loss of hepAtitiS C rnA in SErUm) at tHe end of A 6-12 MoNTH coUrSe Of iNtERfEron, aNd tHe abiliTy to sustaiN thAt Response for 6 mONtHs after the End Of therapy. ThiS apPlicatIoN seEKs supPorT for PEdiatrIC OncolOgy
lebotomy with hepatic iron  concentra tion.  Th e p ri mary  eff icacy endpoint s  are  the response rate (ba sed o nl osso fhepat itis CR NA i n s er um ) a tt he  endofa 6-12month cour seof  interferon, an d the abil ity  to sustaintha t resp on sef or 6mon ths a fter t h e endof therap y. This a p plicati o n  s eeks  support for Pedi a tr i c Oncology
lebotomy with_hepatic iron_concentration. The primary efficacy_endpoints are_the_response rate_(based_on loss of_hepatitis C RNA_in serum) at the_end of a_6-12_month course of interferon, and the ability to sustain that response for 6 months_after_the end_of_therapy._This application seeks support for_Pediatric Oncology